Tema Etfs LLC Raises Holdings in Revolution Medicines, Inc. $RVMD

Tema Etfs LLC increased its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 34.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 126,921 shares of the company’s stock after acquiring an additional 32,694 shares during the period. Tema Etfs LLC’s holdings in Revolution Medicines were worth $5,927,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Bayforest Capital Ltd boosted its position in Revolution Medicines by 21.3% during the third quarter. Bayforest Capital Ltd now owns 7,417 shares of the company’s stock worth $346,000 after acquiring an additional 1,301 shares during the last quarter. Forum Financial Management LP purchased a new position in shares of Revolution Medicines during the 3rd quarter worth approximately $232,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Revolution Medicines in the third quarter valued at $236,000. Clear Harbor Asset Management LLC grew its position in Revolution Medicines by 61.2% in the 3rd quarter. Clear Harbor Asset Management LLC now owns 22,110 shares of the company’s stock valued at $1,033,000 after acquiring an additional 8,394 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Revolution Medicines by 150.4% during the 3rd quarter. SG Americas Securities LLC now owns 10,714 shares of the company’s stock worth $500,000 after buying an additional 6,436 shares during the period. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Revolution Medicines

In other news, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $98.00, for a total transaction of $980,000.00. Following the sale, the chief financial officer owned 108,065 shares of the company’s stock, valued at approximately $10,590,370. The trade was a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Margaret A. Horn sold 75,000 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $100.56, for a total transaction of $7,542,000.00. Following the completion of the transaction, the chief operating officer owned 141,053 shares of the company’s stock, valued at $14,184,289.68. This represents a 34.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 243,792 shares of company stock worth $19,757,740 in the last ninety days. 8.20% of the stock is currently owned by company insiders.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Reports that Merck is in talks to acquire Revolution Medicines for roughly $30–32 billion, a direct M&A bid narrative that can justify a sizable takeover premium and is the primary driver of today’s rally. Merck in talks (WSJ)
• Positive Sentiment: Takeover buzz broadened as media reported additional suitors and renewed buyout interest (markets often bid target stocks higher on competing-acquirer speculation). Takeover buzz, another suitor emerges (Barron’s)
• Positive Sentiment: FDA granted Breakthrough Therapy Designation to zoldonrasib for KRAS G12D-mutant NSCLC — a substantive clinical/regulatory win that strengthens RVMD’s strategic value to acquirers and supports a higher acquisition valuation. Breakthrough Therapy Designation (GlobeNewswire)
• Positive Sentiment: Unusual options activity — a large spike in call buying — indicates aggressive bullish/speculative positioning by traders ahead of or on takeover rumors, amplifying short-term upside momentum. (market reports)
• Neutral Sentiment: The stock experienced a temporary LULD (limit up/limit down) pause during trading, a procedural volatility-control measure that often accompanies sudden price moves but does not change fundamentals.
• Negative Sentiment: Earlier takeover reports referenced AbbVie interest but AbbVie publicly denied talks, which previously triggered volatility and a pullback — a reminder that rumor-driven moves can reverse if potential bidders decline to engage. AbbVie denies talks (Barron’s)
• Negative Sentiment: Revolution remains a loss-making biotech (recent quarterly EPS missed estimates), so absent a takeover premium the stock’s valuation relies on successful late-stage clinical outcomes and eventual commercialization. (company filings/earnings)

Revolution Medicines Trading Up 10.5%

Shares of RVMD stock opened at $118.64 on Monday. The firm’s 50 day moving average price is $76.36 and its two-hundred day moving average price is $54.18. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $121.62. The stock has a market cap of $22.94 billion, a price-to-earnings ratio of -22.95 and a beta of 0.99.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same quarter in the prior year, the business posted ($0.94) earnings per share. On average, analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Royal Bank Of Canada began coverage on shares of Revolution Medicines in a report on Monday, November 3rd. They issued an “outperform” rating and a $77.00 target price on the stock. HC Wainwright boosted their price objective on Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Raymond James Financial raised their price target on Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a report on Friday, October 17th. Stifel Nicolaus initiated coverage on shares of Revolution Medicines in a research note on Wednesday, October 15th. They issued a “buy” rating and a $85.00 price objective on the stock. Finally, UBS Group raised Revolution Medicines to a “strong-buy” rating in a research note on Thursday, December 4th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.